Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.32 USD | -2.58% | -6.21% | -47.40% |
Apr. 15 | RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating | MT |
Apr. 11 | Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating | MT |
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-47.40% | 415M | C+ | ||
-2.31% | 187B | C+ | ||
-3.20% | 106B | C | ||
-5.04% | 66.9B | A | ||
+0.20% | 49.45B | B- | ||
+17.29% | 48B | B- | ||
+4.06% | 40.84B | B+ | ||
+2.36% | 26.25B | A- | ||
+2.07% | 26.48B | B | ||
+12.96% | 24.62B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NVRO Stock
- Ratings Nevro Corp.